A Study of Tumor-Treating Fields (TTFields) in People With Lung Adenocarcinoma

Inclusion Criteria: * The participant (or legally acceptable representative \[LAR\], if applicable) provides written informed consent for the study. * The participant is ≥22 years of age on the day of signing informed consent. * The participant has clinical stage 1A2, 1A3 or IB biopsy-proven lung ADC and is eligible for anatomical resection. * The participant has a lung nodule \>1 cm and suspected lung ADC with a plan to undergo biopsy. * The participant with multiple nodules has one nodule that meets the criteria. * The participant has no history of prior malignancy in the chest or has undergone potentially curative therapy with no evidence of that disease recurrence for 5 years since initiation of that therapy. Exclusion Criteria: * Patients receiving therapy for concurrent active malignancy * Patients with a history of cardiac arrhythmias and/or pacemaker use * Patients with lung nodules \<1cm * Patients with lung nodules that are pure ground glass opacities (GGOs) of any size * Patients with lung nodules that are \<50% solid of any size